Predicting who will develop type 1 diabetes is now cheaper and more accessible, thanks to a new tool based on research ...
Predicting who will develop type 1 diabetes is now cheaper and more accessible, thanks to a new tool based on research ...
After falling short in adults, Novo Nordisk pivots CagriSema into a sweeping global trial targeting childhood obesity.
Children who are given a smartphone before age 12 are at higher risk of insufficient sleep, obesity and depression, a new ...
The COVID-19 pandemic not only disrupted children's education, recreation, and social lives, but it also increased the ...
Novo Nordisk A/S is planning a large study of its next-generation obesity shot CagriSema in children, a sign the drugmaker is pressing forward with the compound despite disappointing results in other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback